First Trust Nasdaq Pharmaceuticals ETF (FTXH) Holdings
FTXH holdings summary
as of Oct 25, 2026- Holdings
- 50 positions listed
- Top 10 weight
- 54.5% of net assets
- Effective holdings
- 23 equal-weight equivalent
- Largest holding
- LLY 7.77% Eli Lilly and Company
- Annual turnover
- 72.3% of the portfolio traded
All FTXH holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly and Company | Healthcare | 7.77% | $88.7M | $1.12T | 42.2 |
| 2 | ABBV | AbbVie Inc. | Healthcare | 7.42% | $84.7M | $504.37B | 80.6 |
| 3 | PFE | Pfizer Inc. | Healthcare | 7.14% | $81.5M | $168.60B | 38.9 |
| 4 | JNJ | Johnson & Johnson | Healthcare | 7.14% | $81.5M | $615.87B | 38.8 |
| 5 | MRK | Merck & Co., Inc. | Healthcare | 6.53% | $74.5M | $360.08B | 115.8 |
| 6 | BIIB | Biogen Inc. | Healthcare | 4.03% | $46.0M | $34.37B | 41.3 |
| 7 | VTRS | Viatris Inc. | Healthcare | 3.82% | $43.5M | $21.43B | — |
| 8 | ZTS | Zoetis Inc. | Healthcare | 3.62% | $41.3M | $32.80B | 13.1 |
| 9 | GILD | Gilead Sciences, Inc. | Healthcare | 3.55% | $40.5M | $193.67B | — |
| 10 | UTHR | United Therapeutics Corporation | Healthcare | 3.52% | $40.2M | $22.87B | 19.1 |
| 11 | AMGN | Amgen Inc. | Healthcare | 3.44% | $39.3M | $233.82B | 26.9 |
| 12 | REGN | Regeneron Pharmaceuticals, Inc. | Healthcare | 3.39% | $38.7M | $81.41B | 19.6 |
| 13 | VRTX | Vertex Pharmaceuticals Incorporated | Healthcare | 3.35% | $38.2M | $126.66B | 28.9 |
| 14 | INCY | Incyte Corporation | Healthcare | 3.27% | $37.3M | $22.92B | 14.4 |
| 15 | BMY | Bristol-Myers Squibb Company | Healthcare | 3.12% | $35.5M | $122.05B | 13.2 |
| 16 | EXEL | Exelixis, Inc. | Healthcare | 2.57% | $29.4M | $15.42B | 19.6 |
| 17 | JAZZ | Jazz Pharmaceuticals plc | Healthcare | 2.44% | $27.8M | $13.65B | 14.4 |
| 18 | ILMN | Illumina, Inc. | Healthcare | 2.08% | $23.8M | $39.64B | 49.0 |
| 19 | HALO | Halozyme Therapeutics, Inc. | Healthcare | 1.70% | $19.4M | $13.83B | 35.6 |
| 20 | MEDP | Medpace Holdings, Inc. | Healthcare | 1.57% | $18.0M | $17.26B | 36.3 |
| 21 | NBIX | Neurocrine Biosciences, Inc. | Healthcare | 1.19% | $13.6M | $13.79B | 19.9 |
| 22 | CRL | Charles River Laboratories International, Inc. | Healthcare | 1.18% | $13.5M | $14.46B | — |
| 23 | ALNY | Alnylam Pharmaceuticals, Inc. | Healthcare | 1.12% | $12.7M | $31.02B | 39.1 |
| 24 | ELAN | Elanco Animal Health Incorporated | Healthcare | 1.12% | $12.7M | $11.76B | — |
| 25 | BMRN | BioMarin Pharmaceutical Inc. | Healthcare | 1.08% | $12.4M | $10.58B | 147.8 |
| 26 | IOVA | Iovance Biotherapeutics, Inc. | Healthcare | 0.79% | $9.0M | $6.17B | — |
| 27 | MRNA | Moderna, Inc. | Healthcare | 0.67% | $7.7M | $87.04B | — |
| 28 | CAI | Caris Life Sciences, Inc. | Healthcare | 0.62% | $7.1M | $8.64B | 18.1 |
| 29 | AMRX | Amneal Pharmaceuticals, Inc. | Healthcare | 0.57% | $6.5M | $6.68B | 39.1 |
| 30 | BCTG | BCTG Acquisition Corp | Financial Services | 0.56% | $6.4M | — | — |
| 31 | TXG | 10x Genomics, Inc. | Healthcare | 0.53% | $6.0M | $9.10B | — |
| 32 | LGND | Ligand Pharmaceuticals Incorporated | Healthcare | 0.51% | $5.9M | $5.89B | 31.1 |
| 33 | ROIV | Roivant Sciences Ltd. | Healthcare | 0.50% | $5.7M | $24.22B | — |
| 34 | GH | Guardant Health, Inc. | Healthcare | 0.49% | $5.6M | $21.28B | — |
| 35 | TWST | Twist Bioscience Corporation | Healthcare | 0.48% | $5.5M | $8.80B | — |
| 36 | ADPT | Adaptive Biotechnologies Corporation | Healthcare | 0.47% | $5.4M | $3.83B | — |
| 37 | SYRE | Spyre Therapeutics, Inc. | Healthcare | 0.47% | $5.4M | $7.47B | — |
| 38 | KYMR | Kymera Therapeutics, Inc. | Healthcare | 0.47% | $5.3M | $8.62B | — |
| 39 | ALKS | Alkermes plc | Healthcare | 0.45% | $5.1M | $6.92B | 108.5 |
| 40 | TGTX | TG Therapeutics, Inc. | Healthcare | 0.45% | $5.1M | $8.26B | 19.6 |
| 41 | PTGX | Protagonist Therapeutics, Inc. | Healthcare | 0.45% | $5.1M | $8.33B | 125.0 |
| 42 | KRYS | Krystal Biotech, Inc. | Healthcare | 0.44% | $5.1M | $9.37B | 39.7 |
| 43 | CORT | Corcept Therapeutics Incorporated | Healthcare | 0.44% | $5.0M | $11.91B | 244.8 |
| 44 | ORKA | Oruka Therapeutics, Inc. | Healthcare | 0.40% | $4.6M | $4.76B | — |
| 45 | TVTX | Travere Therapeutics, Inc. | Healthcare | 0.36% | $4.1M | $4.61B | — |
| 46 | DNTH | Dianthus Therapeutics, Inc. | Healthcare | 0.34% | $3.9M | $4.03B | — |
| 47 | ARWR | Arrowhead Pharmaceuticals, Inc. | Healthcare | 0.34% | $3.9M | $7.90B | — |
| 48 | ELVN | Enliven Therapeutics, Inc. | Healthcare | 0.33% | $3.8M | $2.73B | — |
| 49 | ACAD | ACADIA Pharmaceuticals Inc. | Healthcare | 0.33% | $3.7M | $3.29B | 8.6 |
| 50 | LQDA | Liquidia Corporation | Healthcare | 0.29% | $3.3M | $3.07B | 24.7 |
Weights as a percentage of net assets. Value held = weight × net assets ($1.14B). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
FTXH sector breakdown
| Sector | Weight | Holdings | Largest |
|---|---|---|---|
| Healthcare | 98.4% | 49 | LLY, ABBV, PFE |
| Financial Services | 0.6% | 1 | BCTG |
Sum of the weights of the holdings in each sector.
FTXH top industries
FTXH overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| PJP | Invesco Dynamic Pharmaceuticals ETF | 55.3% | 18 of 28 | 0.57% |
| PBPH | Portfolio Building Block World Pharma and… | 51.2% | 24 of 52 | — |
| IYH | iShares U.S. Healthcare ETF | 48.0% | 31 of 99 | 0.39% |
| FHLC | Fidelity MSCI Health Care ETF | 46.0% | 50 of 334 | 0.07% |
| VHT | Vanguard Health Care ETF | 45.8% | 49 of 406 | 0.10% |
| XLV | Health Care Select Sector SPDR Fund | 45.7% | 17 of 60 | 0.09% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the FTXH portfolio
First Trust Nasdaq Pharmaceuticals ETF holds 50 positions. The ten largest make up 54.5% of the fund, so it behaves like a portfolio of about 23 equally weighted stocks. The biggest positions are Eli Lilly and Company (7.77%), AbbVie Inc. (7.42%), Pfizer Inc. (7.14%), Johnson & Johnson (7.14%), Merck & Co., Inc. (6.53%).
By sector, Healthcare is 98.4%, Financial Services is 0.6%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 25, 2026; positions change as the fund rebalances.
Related: FTXH chart, FTXH performance, FTXH dividends, FTXH valuation, FTXH overview.
FTXH holdings FAQ
How many holdings does FTXH have?
FTXH holds 50 positions as of October 25, 2026.
What are the top 10 holdings of FTXH?
The ten largest holdings are Eli Lilly and Company (7.77%), AbbVie Inc. (7.42%), Pfizer Inc. (7.14%), Johnson & Johnson (7.14%), Merck & Co., Inc. (6.53%), Biogen Inc. (4.03%), Viatris Inc. (3.82%), Zoetis Inc. (3.62%), Gilead Sciences, Inc. (3.55%), United Therapeutics Corporation (3.52%). Together they are 54.5% of the fund.
What percentage of FTXH is Eli Lilly and Company?
Eli Lilly and Company is the largest holding at 7.77% of net assets, about $88.7M of the fund's $1.14B.
How concentrated is FTXH?
The top 10 holdings are 54.5% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) FTXH behaves like a portfolio of about 23 equally weighted stocks.